Current progress in CAR-based therapy for kidney disease

Area of Science:

• Immunology
• Nephrology
• Cell Therapy

Background:

• Immune-mediated kidney diseases present challenges due to poor treatment responses in some patients.
• Existing therapies are insufficient for refractory renal disease cases.
• Engineered T cells offer a novel therapeutic avenue for kidney diseases.

Purpose of the Study:

• To review advancements in chimeric antigen receptor (CAR) T-cell therapies for immune-mediated kidney diseases.
• To highlight the potential of CAR T-cell therapy in basic, translational, and clinical research.
• To explore CAR T-cell applications in targeting autoreactive immune cells and alleviating autoimmune kidney conditions.

Main Methods:

• Genetic modification of T cells to express chimeric antigen receptors (CARs).
• Targeting autoreactive immune cells, including B cells and plasma cells.
• Utilizing effector and regulatory T cells (Tregs) for autoimmune site-specific therapy.

Main Results:

• CAR T-cell therapy enables precise targeting of autoimmune cells implicated in kidney disease.
• Engineered T cells can migrate to sites of autoimmunity, proliferate, and exert suppressive functions.
• This approach offers a novel strategy for alleviating autoimmune manifestations in the kidneys.

Conclusions:

• CAR T-cell therapy represents a promising frontier for treating immune-mediated kidney diseases.
• Genetically modified T cells provide a new mechanism to reduce autoinflammatory events.
• Further research and clinical studies are warranted to fully realize the therapeutic potential of CAR T-cell interventions.